Resources from the same session
When can chemotherapy be omitted and how does menopausal status matter?
Presenter: Christos Sotiriou
Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer
Resources:
Slides
Webcast
Escalating strategies over standard of care as adjuvant treatment therapy in HR+HER2- EBC: Where do we stand?
Presenter: Valentina Guarneri
Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Suzette Delaloge
Session: Risk-adapted strategy in HR+/HER2 negative early breast cancer
Resources:
Slides
Webcast